Market Research Industry Reports

Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Pipeline Review, H1 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Pipeline Review, H1 2018

Summary

According to the recently published report Free Fatty Acid Receptor 4 - Pipeline Review, H1 2018; Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) pipeline Target constitutes close to 9 molecules.

Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Free Fatty Acid Receptor 4 is a G protein-coupled receptor (GPR) encoded by FFAR4 gene. It acts as receptor for medium and long-chain free fatty acids (FFAs). It acts as a receptor for omega-3 fatty acids and mediates robust anti-inflammatory effects, particularly in macrophages and fat cells. The anti-inflammatory effects involve inhibition of TAK1 through a beta-arrestin 2 (ARRB2)/TAB1-dependent effect, but independent of the G (q)/G (11)-coupled pathway. It mediates potent insulin sensitizing and antidiabetic effects by repressing macrophage-induced tissue inflammation. It mediates the taste of fatty acids.

The report Free Fatty Acid Receptor 4 - Pipeline Review, H1 2018 outlays comprehensive information on the Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 6 and 3 respectively. Report covers products from therapy areas Metabolic Disorders, Undisclosed and Gastrointestinal which include indications Type 2 Diabetes, Unspecified, Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4)
- The report reviews Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Overview
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Companies Involved in Therapeutics Development
AstraZeneca Plc
CymaBay Therapeutics Inc
Dompe Farmaceutici SpA
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co Inc
Sancilio & Company Inc
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Drug Profiles
CB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-137647A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize FFAR4 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR120 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FFA4 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR-120 for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR120 for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR120 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by CymaBay Therapeutics Inc, H1 2018
Pipeline by Dompe Farmaceutici SpA, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Johnson & Johnson, H1 2018
Pipeline by Merck & Co Inc, H1 2018
Pipeline by Sancilio & Company Inc, H1 2018
Dormant Projects, H1 2018

List Of Figures

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Molecule Type, H1 2018

USD 3500View Report

Global Free Run Counter Market Research Report 2018

Free Run Counter Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on

USD 2850View Report

Global Fatty Acid Type Rubber Anti-Tack Agents Industry Market Research Report

The Fatty Acid Type Rubber Anti-Tack Agents market revenue was xx.xx Million USD in 2013, grew to xx.xx Million USD in 2017, and will reach xx.xx Million USD in 2023,

USD 2960View Report

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H1 2018

Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H1 2018Acyl CoA Desaturase (Fatty Acid Desaturase or

USD 3500View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 3500
  • Site Licence    USD 7000
  • Enterprise Wide Licence    USD 10500
$ 3500

Reports Details

Published Date : Jun 2018
No. of Pages :31
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube